Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine Chen

Blood (2018) 132 (24): 2546–2554.

https://doi.org/10.1182/blood-2018-06-858852

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece

Blood (2018) 131 (8): 855–863.

https://doi.org/10.1182/blood-2017-08-797886

Published: 2018

Includes: Supplemental data

Journal Articles

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

Blood (2017) 129 (24): 3175–3183.

https://doi.org/10.1182/blood-2016-11-750174

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Ramiro Garzon, Michael Savona, Rachid Baz, Michael Andreeff, Nashat Gabrail, Martin Gutierrez, Lynn Savoie, Paul Morten Mau-Sorensen, Nina Wagner-Johnston, Karen Yee, Thaddeus J. Unger, Jean-Richard Saint-Martin, Robert Carlson, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Sharon Shacham, Michael Kauffman, Richard Stone

Blood (2017) 129 (24): 3165–3174.

https://doi.org/10.1182/blood-2016-11-750158

Published: 2017

Includes: Supplemental data

Journal Articles

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Trinayan Kashyap, MS, Irfana Muqbil, Amro Aboukameel, Boris Klebanov, MA, MS, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, William Senapedis, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 4131.

https://doi.org/10.1182/blood.V128.22.4131.4131

Published: 2016

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Erkan Baloglu, PhD, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 1563.

https://doi.org/10.1182/blood.V128.22.1563.1563

Published: 2016

Journal Articles

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Trinayan Kashyap, MS, Boris Klebanov, MA, MS, Christian Argueta, PhD, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD

Blood (2016) 128 (22): 5660.

https://doi.org/10.1182/blood.V128.22.5660.5660

Published: 2016

Journal Articles

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Blood (2016) 128 (22): 491.

https://doi.org/10.1182/blood.V128.22.491.491

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

Christian Argueta, PhD, Hua Chang, PhD, Trinayan Kashyap, MS, Sivan Elloul, PhD, Sharon Friedlander, PhD, Margaret S. Lee, PhD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, William Senapedis, PhD, Erkan Baloglu, PhD MBA

Blood (2016) 128 (22): 3298.

https://doi.org/10.1182/blood.V128.22.3298.3298

Published: 2016

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Blood (2015) 126 (23): 317.

https://doi.org/10.1182/blood.V126.23.317.317

Published: 2015

Journal Articles

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Julia Etchin, PhD, Alla Berezovskaya, Amy Saur Conway, Weihsu Claire Chen, PhD, Erkan Baloglu, PhD, Yosef Landesman, PhD, William Senapedis, PhD, Joel Ellis, PhD, Dilara McCauley, PhD, Richard M. Stone, MD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Michael Kauffman, Sharon Shacham, Jean C.Y. Wang, MDPhD, A. Thomas Look, MD

Blood (2015) 126 (23): 326.

https://doi.org/10.1182/blood.V126.23.326.326

Published: 2015

Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD

Blood (2015) 126 (23): 3048.

https://doi.org/10.1182/blood.V126.23.3048.3048

Published: 2015

Journal Articles

Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma

Dirk Daelemans, PhD, Eline Boons, Els Vanstreels, Maarten Jacquemyn, Tatiane C Nogueira, Jasper E Neggers, Thomas Vercruysse, Joost van den Oord, Sharon Tamir, Michael Kauffman, MD PhD, Sharon Shacham, Yosef Landesman, PhD, Robert Snoeck, Christophe Pannecouque, Graciela Andrei

Blood (2015) 126 (23): 2751.

https://doi.org/10.1182/blood.V126.23.2751.2751

Published: 2015

Journal Articles

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Jeffrey A Zonder, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Leonor A Stephens, PhD, Kathryn McDonnell, Rebecca Uribe, Shaun Rosebeck, PhD, Tami Rashal, MD, Hagop Youssoufian, MD, Sarah Henry, Sharon Shacham, Michael Kauffman, MD PhD, Todd Zimmerman, MD, Theodore Karrison, PhD

Blood (2015) 126 (23): 4223.

https://doi.org/10.1182/blood.V126.23.4223.4223

Published: 2015

Journal Articles

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Parvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, Jessica Hofstetter, Alison Walker, Katherine Walsh, Bhavana Bhatnagar, Rebecca Klisovic, Sumithira Vasu, Mitch A. Phelps, Steven Devine, Sharon Shacham, Michael Kauffman, Guido Marcucci, William Blum, Ramiro Garzon

Blood (2015) 125 (17): 2689–2692.

https://doi.org/10.1182/blood-2014-10-607648

Published: 2015

Includes: Supplemental data

Journal Articles

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

Blood (2015) 125 (11): 1772–1781.

https://doi.org/10.1182/blood-2014-08-588855

Published: 2015

Includes: Supplemental data

NARROW

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only